Durlobactam sodium
Based on 6 publication(s) in Google Scholar
Durlobactam sodium salt (ETX2514) is a broad-spectrum β-lactamase inhibitor with IC50s of 4, 14 and 190 nM for Class A KPC-2, Class C AmpC and Class D OXA-24, respectively. For the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.
For research use only. We do not sell to patients.
- Purity: 99.62%
- CAS No.: 1467157-21-6
- Formula: C8H10N3NaO6S
- Molecular Weight:299.24
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Durlobactam sodium
More-
Microbiological Assay
-
Microbiological Assay
-
Microbiological Assay
-
Microbiological Assay
-
Microbiological Assay
Biological Activity
IC50: 4 nM (Class A KPC-2), 14 nM (Class C AmpC), 190 nM (Class D OXA-24)[1].
Durlobactam sodium salt (ETX2514) inhibits against OXA-24/40 and OXA-23 from A. baumannii strains with MICs of 4 μg/mL and 2 μg/mL, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1467157-21-6
-
Appearance Solid
-
Molecular Weight 299.24
-
Formula C8H10N3NaO6S
-
Color White to light yellow
-
SMILES
NC([C@H]1[N@@]2C(N([C@H](C=C1C)C2)OS(=O)(O[Na])=O)=O)=O
-
Synonyms
ETX2514
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Antimicrob Agents Chemother
Antibacterial activity of enmetazobactam against Acinetobacter spp.: a molecular dissection of mechanism of action and resistance determinants. [Abstract]2025 Dec 22:e0120625. PMID: 41427713
Durlobactam sodium purchased from MedChemExpress. Usage Cited in: Antimicrob Agents Chemother. 2025 Dec 22:e0120625. [Abstract]
Durlobactam sodium (DUR; 4 μg/mL) in combination with enmetazobactam exhibited markedly stronger potency against multidrug-resistant A. baumannii strains, with MIC50/90 of 2/2 mg/L, compared to enmetazobactam alone (MIC50/90 of 64/64 mg/L).
Durlobactam sodium purchased from MedChemExpress. Usage Cited in: Antimicrob Agents Chemother. 2025 Dec 22:e0120625. [Abstract]
Durlobactam sodium (DUR; 4 μg/mL) in combination with enmetazobactam exhibited potency against ATCC 17978 transformants collection expressing OXA-like carbapenemase genes.
-
Antimicrob Agents Chemother
Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases. [Abstract]2024 Nov 6;68(11):e0077524. PMID: 39365068 -
Int J Infect Dis
Susceptibilities of cefiderocol, meropenem-xeruborbactam, cefepime-taniborbactam, aztreonam-avibactam, and sulbactam-durlobactam against imipenem-non-susceptible Gram-negative bacilli in Taiwan. [Abstract]2025 Dec 4:163:108279. PMID: 41349864
Durlobactam sodium purchased from MedChemExpress. Usage Cited in: Int J Infect Dis. 2025 Dec 4:163:108279. [Abstract]
Durlobactam sodium (DUR) showed Antimicrobial susceptibilities of imipenem-non-susceptible Gram-negative bacteria.
Durlobactam sodium purchased from MedChemExpress. Usage Cited in: Int J Infect Dis. 2025 Dec 4:163:108279. [Abstract]
Durlobactam sodium (DUR) showed antimicrobial susceptibility for A. baumannii.
-
Microbiol Spectr
Susceptibility toward cefiderocol and sulbactam-durlobactam in extensively drug-resistant Acinetobacter baumannii detected from ICU admission screening in Hanoi, Vietnam, 2023. [Abstract]2025 Jun 9:e0083225. PMID: 40488459 -
Durlobactam sodium purchased from MedChemExpress. Usage Cited in: Preprints. 2025 Nov 24.
Durlobactam sodium (DUR; 128 mg/L) isolated fourteen mutants selection, seven of which showed high level resistance, with an agar MIC >128 mg/L.
-
Solvent & Solubility
H2O : ≥ 100 mg/mL (334.18 mM)
DMSO : 50 mg/mL (167.09 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Durand-Réville TF, et al. ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat Microbiol. 2017 Jun 30;2:17104. [Content Brief]
[2]. González-Bello C. Recently developed synthetic compounds with anti-infective activity. Curr Opin Pharmacol. 2019 Oct;48:17-23. [Content Brief]
[3]. Barnes MD, et al. Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent. mBio. 2019 Mar 12;10(2):e00159-19. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 3.3418 mL | 16.7090 mL | 33.4180 mL | 83.5450 mL |
| 5 mM | 0.6684 mL | 3.3418 mL | 6.6836 mL | 16.7090 mL | |
| 10 mM | 0.3342 mL | 1.6709 mL | 3.3418 mL | 8.3545 mL | |
| 15 mM | 0.2228 mL | 1.1139 mL | 2.2279 mL | 5.5697 mL | |
| 20 mM | 0.1671 mL | 0.8354 mL | 1.6709 mL | 4.1772 mL | |
| 25 mM | 0.1337 mL | 0.6684 mL | 1.3367 mL | 3.3418 mL | |
| 30 mM | 0.1114 mL | 0.5570 mL | 1.1139 mL | 2.7848 mL | |
| 40 mM | 0.0835 mL | 0.4177 mL | 0.8354 mL | 2.0886 mL | |
| 50 mM | 0.0668 mL | 0.3342 mL | 0.6684 mL | 1.6709 mL | |
| 60 mM | 0.0557 mL | 0.2785 mL | 0.5570 mL | 1.3924 mL | |
| 80 mM | 0.0418 mL | 0.2089 mL | 0.4177 mL | 1.0443 mL | |
| 100 mM | 0.0334 mL | 0.1671 mL | 0.3342 mL | 0.8354 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.